PD-L1ATTAC mice reveal the potential of targeting PD-L1 expressing cells in cancer therapy
Fueyo-Marcos, E.; Fustero-Torre, C.; Lopez, G.; Anton, M. E.; Al-Shahrour, F.; Fernandez-Capetillo, O.; Murga, M.
Show abstract
Antibodies targeting the PD-1 receptor and its ligand PD-L1 have shown impressive responses in some tumors of bad prognosis. We hypothesized that the selective elimination of PD-L1 expressing cells could similarly have antitumoral effects. To address this question, we developed an inducible suicidal knock-in mouse allele of Pd-l1 (PD-L1ATTAC) which allows for the tracking and specific elimination of PD-L1-expressing cells in adult tissues. Elimination of PD-L1 expressing cells from the mouse peritoneum increased the septic response to lipopolysaccharide (LPS), due to an exacerbated inflammatory response to the endotoxin. In addition, mice depleted of PD-L1+ cells were resistant to colon cancer peritoneal allografts, which was associated with a loss of immunosuppresive B cells and macrophages, concomitant with an increase in activated cytotoxic CD8 T cells. Collectively, these results illustrate the usefulness of PD-L1ATTAC mice and provide genetic support to the concept of targeting PD-L1 expressing cells in cancer therapy.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Complementary CRISPR screen highlights the contrasting role of membrane-bound and soluble ICAM-1 in regulating antigen specific tumor cell killing by cytotoxic T cells 95%
- Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy 95%
- Citalopram exhibits immune-dependent anti-tumor effects by modulating C5aR1+ TAMs 94%
Similar papers in this journal
- Drug tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanisms 93%
- Targeting the mitochondrial RNA methyltransferase TRMT61B reveals new therapeutic opportunities in aneuploid cancer cells 92%
- RIPK3 upregulation confers robust proliferation and collateral cystine-dependence on breast cancer recurrence 92%
Similar papers in this journal
- LSD1 inhibition improves efficacy of adoptive T cell therapy by enhancing CD8+ T cell responsiveness. 95%
- Loss of Rnf31 and Vps4b sensitizes pancreatic cancer to T cell-mediated killing 95%
- Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor resistant HER2-positive breast cancer 94%